Chemotargets and the CRG ally to accelerate the development of new treatments

26 October 2021

Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical needs in different fields including cancer.

Barcelona, October 26th, 2021. The development of new treatments for diseases requires the identification of potential targets – for example proteins or enzymes – that are critical for the onset and progression of the disease. After finding a candidate, researchers need to screen thousands of potential molecules that might interfere with the target and test for their effectiveness and safety. This ‘bench to bedside’ process is expensive and takes many years of research before benefiting patients.

Recent technological advances in artificial intelligence, advanced computing and mass-scale data analysis is accelerating the drug development process, sometimes reducing the timescale of the process by years.

Chemotargets, a global leader in the field, develops computational platforms for the design, optimization and safety evaluation of drugs. The biotech firm’s cutting-edge computational technologies can rapidly design potential new drug candidates for therapeutic targets that are difficult to treat and for which no identified drugs currently exist.

The new partnership will leverage the CRG’s fundamental knowledge on the complexity of life, as well as its expertise in identifying potential new therapeutic targets in emerging fields of cancer biology. 70% of the CRG’s projects with translational potential focus on the validation of new therapeutic targets for the treatment of different diseases such as cancer, fibrosis, eye diseases, blood diseases or diseases that cause inflammation.

The first project under the agreement involves a new target identified by Isabelle Vernos’ group in the CRG’s Cell and Developmental Biology research programme. The Vernos group has world-leading expertise on fundamental biological processes such as cell division with a focus on the mechanisms of spindle assembly and chromosome segregation fidelity, processes that when dysregulated can be associated with infertility and cancer.

The CRG’s strengths lie in our profound understanding of fundamental aspects of human biology, our world-leading expertise in the design and engineering of proteins, and our state-of-the-art technological platforms in genomics, proteomics, screening, tissue engineering and organoids. Partnering with a high-profile company like Chemotargets will be a vital boost to leverage our know-how and put it to use for drug discovery projects for the benefit of patients in need,” says Luis Serrano, director of the CRG.

"We welcome this collaboration and look forward to working with the CRG on several levels. In addition to world-class fundamental biology, the infrastructure to rapidly design medications specific for the phenotype and genotype of both disease and patient in collaboration with the CRG brings a critical new dimension to Chemotargets’ growing internal pipeline.” Dr. Scott Boyer, CEO, Chemotargets.

 

Chemotargets was founded in 2006 as a spin-off of the systems pharmacology research group of Dr. Jordi Mestres under the auspices of the IMIM Hospital del Mar Medical Research Institute. The company, with headquarters located in the Barcelona Science Park (PCB), offers state-of-the-art artificial intelligence-driven methodologies with predictive capabilities in the fields of virtual screening, chemical design, pharmacology and drug safety. Its goal is to help the pharmaceutical industry accelerate drug discovery and development programs, while improving cost-effectiveness and safety. 

The CRG is a biomedical research center based in Barcelona. Created in December 2000, the CRG is home to more than four hundred interdisciplinary scientists focused on understanding the complexity of life, from the genome to the cell and the entire organism. The CRG is a center with a unique research model, focused on recruiting internationally renowned group leaders. The CRG is a member of the Barcelona Institute of Science and Technology (BIST) and a CERCA centre within the research system of the Catalan Government.
 

 

Media contacts: 

Chemotargets: Dr. Scott Boyer, CEO (scott.boyer@chemotargets.com)

PCB: Azucena Berea, Press Officer (aberea@pcb.ub.cat)

CRG: Omar Jamshed, Press Officer (omar.jamshed@crg.eu)

 

 

 

Chemotargets launches Clarity PV, a new web-based platform for translational safety and pharmacovigilance

05 July 2021

This week Chemotargets announces the launch of Clarity PV, a new product for translational safety and pharmacovigilance professionals.

Barcelona, July 5th, 2021. Chemotargets launches Clarity PV, a new web-based platform for translational safety and pharmacovigilance. Clarity PV (https://claritypv.com) contains highly-curated structured and integrated data covering the entire safety lifetime of a drug, from safety pharmacology, through preclinical toxicology and clinical safety, up to post-marketing reports, allowing for a seamless connection and traceability of safety signals across all drug discovery phases. Clarity PV has been thoroughly validated to alert on potential drug safety signals, in most cases identified months, and even years, in advance to any conference communication, company statement or risk awareness from pharmacovigilance committees. The platform includes new analytics tools and reporting options to assist the user in performing periodic safety surveillance of the drugs and drug classes of interest.

Clarity PV will be officially presented for the first time this week at the 48th Annual Meeting of the Japanese Society of Toxicology

Please, contact info@chemotargets.com to request a demo license for a trial period.

Chemotargets has been awarded the Innovative SME Seal from the Spanish Ministry of Science and Innovation

03 June 2021

The Innovative SME Seal, valid for three years, recognizes the high level of innovation in the projects, products and services of Chemotargets. 

Barcelona, June 1st, 2021. Chemotargets has been awarded the Innovative SME Seal from the Spanish Ministry of Science and Innovation. The seal, valid for three years, recognizes the innovative character of the Chemotargets CLARITY Suite, of the drug discovery services offered to pharma and biotech companies worldwide, and the participation in competitive R+D European projects financed by Horizon 2020.


We are absolutely delighted to receive this Innovative SME Seal from the Spanish Ministry of Science and Innovation that recognizes 15 years of commitment to deliver highly innovative and informative software products for drug discovery and development” commented Dr. Jordi Mestres, Chemotargets CSO. “We are working towards delivering a conceptually new suite of purposely designed analytics tools that cover the entire drug discovery process, from the identification and optimization of more efficacious and safer drug candidates to the translational safety and postmarketing surveillance of drugs”, added Dr. Mestres.

Chemotargets Announces First AI-Designed Drug for Huntington’s Disease to Enter Clinical Trials

22 April 2021

In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven de novo drug design methods in collaboration with Gaylan Bio to rapidly design novel molecules which would bind to the previously ’undruggable’ Huntington’s Disease target.

Barcelona, 22 April 2021 - Huntington’s Disease (HD) is a neurodegenerative disorder that affects thousands of patients worldwide. There is currently no cure or disease modifying treatment for HD. This is why US-based company Galyan Bio and Barcelona-based Chemotargets joined efforts to design a first in class drug for HD. The result has been the generation of a first-in-class drug candidate for HD. Galyan Bio plans to start clinical trials in HD in 2022. Galyan Bio’s new treatment is intended to slow down the disease in symptomatic patients and delay manifestation of HD in symptom-free gene carriers.

The development of new molecules through medicinal chemistry has always been a laborious and costly process. We used Chemotargets drug discovery platforms to speed up the process considerably. Based on Chemotargets’ AI-driven de novo designs, we selected and tested 49 compounds. Our expectations were exceeded as we identified 6 compounds which could actually bind to our drug target. The optimization of one of those hits led to a preclinical drug candidate for HD” said Dr. Marius Galyan, CEO of Galyan Bio.

Chemotargets’ proprietary ProSurfScan AI-driven de novo drug design platform uses novel methods of agnostically scanning the target protein to perform a virtual fragment-based screening of all possible drug binding areas. Fragments are then automatically linked to design effective binding molecules. The AI-driven methods employed by Chemotargets are particularly suited to novel, difficult, previously unaddressable targets as well as drug targets for which high isoform selectivity is required. ProSurfScan is part of a complete suite of AI-driven drug discovery tools which are in routine use within Chemotargets that include CLARITY®, the industry-leading software platform for anticipating the safety of new drug molecules. CLARITY® is currently in use in many of the top pharmaceutical companies worldwide and at the US Food and Drug Administration.

We are absolutely delighted to have effectively contributed to delivering a first-in-class drug candidate for HD. Having a tangible proof-of-principle that our de novo designs lead to progressible bioactive small molecules in a prospective drug discovery project means a world to us. This means that our in-silico platform is ready to address other novel, difficult, protein targets for which no therapeutic modalities exist.” said Dr. Jordi Mestres, CSO of Chemotargets.

First and foremost, we are grateful for the opportunity to contribute to a possible therapeutic alternative for Huntington’s Disease patients. I am, quite frankly, not surprised by the experimental activity results of the molecules arising from the de novo design. ProSurfScan has repeatedly demonstrated its ability to design novel, selective molecules which bind to novel and difficult targets in our internal programs and will no doubt continue to do so. Although artificial intelligence is necessary in nearly everything we do at Chemotargets, we are a company focused on helping patients. By using AI to aid decisionmaking in the design and development of novel therapeutics, our mission will always be to facilitate the development of safer, more effective therapeutics in less time and at a lower cost that was possible in the past. We are pleased that, for Huntington’s Disease patients, we have been able to demonstrate that potential.” said Dr. Scott Boyer, CEO of Chemotargets.

Galyan Bio, Inc. is a startup company located in Berkeley, California (USA). Galyan is developing first-in-class orally available small molecules for neurodegenerative diseases, cancer and aging. It was founded in 2019 by Dr. Marius Galyan.

Chemotargets is a biotech company focused on the development of state-of-the-art predictive analytics platforms for drug discovery and the design of novel bioactive small molecules for challenging difficult-to-address targets. It was founded in March 2006 by Dr. Jordi Mestres as a spin-off from the IMIM Hospital del Mar Medical Research Institute, a leading health research institute based in Barcelona, Catalonia (Spain). Chemotargets has its headquarters at the Parc Científic de Barcelona.

Chemotargets CLARITY® (Seal of Excellence project from the European Commission) uses artificial intelligence on carefully-curated data to connect small molecules, protein targets, safety events, and therapeutic indications with the help of state-of-the-art analytics tools. The platform can be used to identify the probable primary and secondary targets of molecules and their predicted metabolites by rapidly profiling through consensus ligandbased models of 4,799 proteins built from affinity data for almost 3 million molecules. In addition, machine learning models of 1,278 safety endpoints were constructed from data carefully extracted from over 39 million spontaneous reports, including hundreds of safetyrelated mechanisms annotated with preclinical toxicity and clinical safety issues. Beyond predictive pharmacology and safety, the CLARITY Suite of products can be applied to drug repurposing, deconvolution of phenotypic screens, translational safety and pharmacovigilance.

ProSurfScan is a novel AI-based method developed at Chemotargets to scan protein surfaces in search for amino acid environments likely to interact with chemical fragments. It uses convolutional neural networks derived from all known protein structures to perform a virtual fragment screening of a complete protein surface. The approach is especially suited for addressing novel, difficult to address targets, including protein-protein interactions, and a variety of modes of action, such as allosteric interactions.

 

Media Contacts:

Gaylan Bio: Dr. Marius Galyan, CEO (marius@galyanbioinc.com)

Chemotargets: Dr. Scott Boyer, CEO (scott.boyer@chemotargets.com)

Dr. Scott Boyer joins Chemotargets as new CEO

14 October 2020

With the new incorporation, the company consolidates its transition from a software business to an AI-driven biotech company.

Barcelona, 6 October 2020 - Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO with the aim to consolidate its transition from a software business to a key player in the biotech sector. Dr Boyer joins Chemotargets from Swedish drug development company Klaria, where he has been CEO/CSO since 2015 and will continue as a member of the Board of Directors and as a scientific advisor. Prior to joining Klaria, he was Chief Scientist at AstraZeneca (Sweden), with global responsibility for molecular and investigational toxicology across the company, and a member of the company’s senior management team.  Prior to AstraZeneca, Dr. Boyer was a senior scientist at Pfizer Central Research in the US.

Scott Boyer has a PhD in Molecular Toxicology from the University of Colorado, Boulder, and he completed an NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute in Stockholm. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. 

I have known Jordi Mestres for a long time, and I have always admired Chemotargets for being one of those companies that did things correctly. Its focus on data quality combined with sensible and appropriate applications of artificial intelligence/machine learning has put Chemotargets as the number one platform in the world in its field. In this new stage as a biotech company, a new universe of possibilities is opening up to us in the development of new drugs”, said the new CEO. Boyer, who brings to the company an extended experience in computation applied to drug discovery and development, is looking forward to “apply artificial intelligence/machine learning techniques along with computationally-supported pharmacodynamic analysis to every aspect of drug discovery and development, especially safety. There are not many companies, if any, that can do this. We have the tools, the data sets and we know which technologies can be applied to the different types of problems.

Jordi Mestres said: "Scott Boyer is one of the most authoritative individuals in our field and it is a privilege to have him as the new CEO of Chemotargets. His appointment comes naturally after the recent announcement of the company to transition from a software business to a biotech with its own drug discovery pipeline". Dr Mestres has been Chemotargets’ CEO since its foundation as a spin-off from the Barcelona’s Hospital del Mar Medical Research Institute (IMIM) in 2006.

Dr. Boyer’s short-term goals include closing the Series A funding round opened in July with the aim of expanding Chemotarget’s activity. Dr. Boyer will also build strategic alliances with partners in the biotech and pharmaceutical sector to consolidate the company as a key player in the global ‘AI-driven’ biotech market. 

Chemotargets presently has developed a full suite of unique AI-based tools to identify, optimize and ensure the optimal safety profile of new drug candidates.  The application of these tools, in concert, ensures rapid identification of proprietary molecules capable of addressing significant unmet medical needs.  One of the most relevant examples of the innnovations within Chemotargets is its safety profiling software CLARITYⓇ.  A CLARITYsoftware license was acquired this year by the US Food and Drug Administration (FDA).  CLARITYis a technology that defines the efficacy and safety profiles of new drugs and in addition to the US FDA, has been licensed by a large number of pharmaceutical companies ranging from small biotechs to large international organizations.

Genesis Biomed, a well-established consultancy firm in the health and biotech sectors, and CREA Inversión, an M&A boutique advisory firm specialised in corporate transactions and financing, are advising Chemotargets in the transformation of the company. 

About Chemotargets

Chemotargets was founded in March 2006 as a spin-off from Dr. Mestres’ Research Group on Systems Pharmacology under the auspices of the IMIM Hospital del Mar Medical Research Institute, a leading academic center of excellence based in Barcelona. With its offices at the Parc Científic de Barcelona, Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by the continuous research and development of new methods. Since May 2017, Prous Institute for Biomedical Research has made a strategic investment in Chemotargets SL  which has allowed CLARITYⓇ product development to be accelerated and new capabilities to be acquired in order to support the company’s vision and quickly address customers’ needs. CLARITY® is currently used worldwide by more than 20 top pharmaceutical companies, academic institutions and non-for-profit organizations, such as the FDA.

About GENESIS Biomed

Founded in 2017, GENESIS Biomed is a consulting firm that offers services to companies and organisations in the biotech and health sectors. With headquarters in Barcelona and Madrid and with a clear international vocation, it has a team of 10 experienced and highly qualified professionals. The company has raised over 45 million euros for its clients, closing successful investment rounds for Peptomyc, Anaconda Biomed, GlyCardial Diagnostics, AptaTargets and Leukos Biomed among others. 

About CREA Inversión

CREA Inversión is an M&A boutique advisory firm specialised in corporate transactions and financing (equity, debt and alternative). Founded in 2011 by five partners with an extensive experience in financial management, it has offices in Barcelona, Madrid, Pamplona and San Sebastián. It has a team of over 30 professionals and has successfully closed over 100 financial operations. 

 

Chemotargets enters a new phase of growth - from a software company to a drug discovery biotech.

25 May 2020

This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between both institutions.

Chemotargets has entered into a strategic alliance with the IMIM Hospital del Mar Medical Research Institute to accelerate the design of new cancer therapies. This alliance will allow Chemotargets to build an oncology pipeline with biologically relevant and therapeutically validated targets at IMIM.

More information here.

 

The FDA licenses Chemotargets CLARITY platform

06 May 2020

The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest.

This contract is meant to directly address the FDA's requirement for a computational method which can predict potential molecular targets from chemical structure and provide a user-friendly environment for analysis of results. Molecular targets identified with high confidence by CLARITY® may be evaluated by FDA/CDER for their association with adverse events, addiction liability, or their association with disease within the specified indication(s).

A previous collaboration with FDA/CDER focused on predicting on-target and off-target activities using known in vitro pharmacology data for small molecules and associating them with drug safety data coming from post-marketing spontaneous reports. A tangible outcome of the collaboration between FDA/CDER and Chemotargets has been the incorporation of CLARITY® as part of the FDA's Public Health Assessment via Structural Evaluation (PHASE) initiative for assessing the abuse risk that new drugs could pose to public safety (Clin. Pharmacol. Ther. 2019, 106, 116-122 and PLoS ONE 2020, 15, e0229646).

Chemotargets opens an investment round to enter a new phase of growth

16 April 2020

GENESIS Biomed and CREA Inversión will advise in the funding, which will allow the company to expand its activity in the discovery of new drugs

Barcelona, 14 April 2020 - Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to become a biotechnology company that will develop new medicines in multiple therapeutic areas, with an initial focus on oncology. Founded in 2006 as a spin-off from Dr. Jordi Mestres’ Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute, a leading academic centre of excellence based in Barcelona, Chemotargets is opening an investment round to undertake the transformation of its business model. 

Genesis Biomed, a well-established consultancy firm in the health and biotech sectors, and CREA Inversión, an M&A boutique advisory firm specialised in corporate transactions and financing, will advise Chemotargets in this transformation. 

“We are very motivated to begin a new stage of growth and to discover new bioactive molecules in collaboration with public research centres and pharmaceuticals companies. On this basis, we will consider the creation of new spin-off entities that will discover and develop new potential drugs,” says Chemotargets CEO Dr. Jordi Mestres. The company has developed the ProSurfScan technology, which allows the generation of bioactive molecules using state-of-the-art structure-based, artificial intelligence and data-mining methods for novel therapeutic targets and new interaction modalities (protein - protein, allosteric modulators, etc.). 

In parallel, Chemotargets will continue to offer its services to pharmaceutical companies and research centres. Its main business is the provision of services to the life sciences sector based on CLARITYⓇ (European Commission’s  Seal of Excellence), a technology that defines the efficacy and safety profiles of new drugs. CLARITYⓇ’s license has been acquired this year by the US  Food and Drug Administration (FDA) among other international bodies and companies.

The combined use of CLARITY® and ProSurfScan, to simultaneously optimize the safety and efficacy of newly-discovered therapies, will position Chemotargets as a unique global player in the finding of more effective and safer drugs.

In the transition, a new leadership team will be formed to advance both the current business model of Software and Services and in addition, the rapid development of novel therapeutics in close collaboration with leading research centers and pharmaceutical industry.

 

A steadfast commitment in difficult times

The health and social crisis caused by SARS-CoV-2 pandemic has encouraged the company to pursue its principles: “We founded Chemotargets to resolve complex biomedical challenges and we have an obligation to join efforts to find solutions to this major challenge,” says Jordi Mestres.

GENESIS Biomed CEO Josep Lluís Falcó is “excited to start working with Chemotargets in collaboration with CREA Inversión. It is very positive that the sector does not stop despite this severe health crisis. We are extremely proud of undertaking such an ambitious project with CREA Inversión, being the first major collaboration as part of our strategic alliance.”

 

About Chemotargets

Chemotargets SL was founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, a leading academic center of excellence based in Barcelona.  Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at Dr. Mestres’ lab. Since May 2017, Prous Institute for Biomedical Research has made a strategic investment in Chemotargets SL  which has allowed CLARITYⓇ product development to be accelerated and new capabilities to be acquired in order to support the company’s vision and quickly address customers needs.

 

About GENESIS Biomed

Founded in 2017, GENESIS Biomed is a consulting firm that offers services to companies and organisations in the biotech and health sectors. With headquarters in Barcelona and Madrid and with a clear international vocation, it has a team of 10 experienced and highly qualified professionals. The company has raised over 45 million euros for its clients, closing successful investment rounds for Peptomyc, Anaconda Biomed, GlyCardial Diagnostics, AptaTargets and Leukos Biomed among others. 

 

About CREA Inversión

CREA Inversión is an M&A boutique advisory firm specialised in corporate transactions and financing (equity, debt and alternative). Founded in 2011 by five partners with an extensive experience in financial management, it has offices in Barcelona, Madrid, Pamplona and San Sebastián. It has a team of over 30 professionals and has successfully closed over a 100 financial operations. 

CANCELED - Chemotargets SL will present CLARITY® V4.0 at SOT2020, 15-19th March 2020, Anaheim (US)

02 March 2020

PS: SOT conference has been canceled due to the global situation regarding COVID-19

 
Chemotargets will participate at the Society of Toxicology Annual meeting (SOT2020) in Anaheim, California (US), March 15-19, 2020. We will be presenting Chemotargets CLARITYⓇ, a data-driven integrative analytics platform for small molecule pharmaceuticals, including advanced informatics solution for predictive off-target pharmacology (based on patents information) and safety of compounds (based on FDA FAERS data), and their metabolites. CLARITY is used by top pharma and regulatory bodies, including FDA CDER.

Join us at booth number 657 (together with Bioinfogate) for a CLARITYⓇ demonstration. The current distribution (version 4) includes a new module, the MedChem Explorer, that facilitates SAR analyses and Scaffold hopping, enabling the exploration by molecule scaffolds and the analysis of associated pharmacology, safety and therapeutic indications data. For further information or to schedule a meeting during the conference, please contact info@chemotargets.com.

Chemotargets SL launches the CLARITY® V4.0 release

04 November 2019

Updates on data and models, and a new explorer module to navigate by scaffolds and molecules related data, the MedChem Explorer.

This month, we are pleased to announce the launch of CLARITY v4.0, with a series of improvements among the different modules in terms of interface results presentation, optimized responsiveness and ability to save and restore navigation states as general performance aspects. 

 

Highlights of the new version:

  • Updated pharmacology models (the latest 2019 data from public sources and patents)
  • Updated toxicology models (new model types (preclinical, clinical and postmarketing)
  • Updated FAERS data and signals (reports up to 2019Q2)
  • The FAERS Explorer module has been improved with additional analytics and the platform will work for quarterly updates available via patch
  • The Predictive Analytics module now shows new options for customized panels creation and includes models details for confidence assessment via models fiches presentation
  • The basket tool now allows for selecting molecules with structures available to basket and run a prediction and/or get a file with IDs from several chemical providers
  • NEW in this distribution: A new add-on module, the MedChem Explorer, an interactive tool that facilitates SAR analyses and Scaffold hopping, enabling the exploration of molecules by Murcko scaffold and the analysis of associated pharmacology, safety and therapeutic indications data. Including these chemical providers catalogues: ChemBridge, Life Chemicals and TargetMol.

Contact us to request a demo at clarity@chemotargets.com

Chemotargets CLARITY has been awarded the Seal of Excellence from the European Commission

12 July 2019

The Seal of Excellence certifies the high-quality of the CLARITY proposal aimed at enhancing its data coverage, artificial intelligence approaches and analytics tools for drug discovery.

 

Barcelona, July 11th, 2019. Chemotargets recently submitted a Horizon 2020's SME Instrument Phase 2 project proposal (880844) entitled "CLARITY: Intelligence and Discovery Platform for Predictive Pharmacology and Safety of Small Molecules" in which a second generation of the Chemotargets CLARITY® platform based on artificial intelligence approaches and state-of-the-art analytics tools was described. Following the evaluation by an international panel of independent experts, the proposal was scored as a high-quality project in a highly competitive evaluation process, meaning that the project passed all stringent Horizon 2020 assessment thresholds for the three award criteria (Excellence, Impact, and Quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020. Accordingly, the project CLARITY was awarded a Seal of Excellence, a high-quality certificate digitally signed by the Commissioners as a political commitment from the European Commission.

“We are absolutely delighted to receive this Seal of Excellence from the European Commission for the CLARITY proposal” commented Dr. Jordi Mestres, Chemotargets CEO. “We are committed to keep on building the capabilities in CLARITY to accelerate the process of generating more efficacious and safer drugs and to become an indispensable tool from drug discovery to postmarketing surveillance”, added Dr. Mestres.

About Chemotargets CLARITY® 

Chemotargets CLARITY® is an integrative analytics platform that consolidates chemistry, pharmacology, safety, and therapeutic intelligence (both known and predicted) of drugs and enables predictive pharmacology and safety of novel small molecules as well as metabolite generation and profiling.  Multiple independent computational methods (including SAR, SAS and MLM) are used in a consensus approach to increase confidence in prediction results.

 

Based on an expertly curated set of 4.4 million in vitro pharmacology data points for 2.6 million molecules derived from patents, journals and public databases, CLARITY-v3.0 offers pharmacology models for 3,601 mechanism of action targets and off-targets. In addition, safety models based on 11.1 million post-marketing spontaneous reports from the US FDA Adverse Event Reporting System (FAERS) are also available for 520 safety events. Preclinical and clinical safety assessment is complemented with a predictive drug metabolism module based on a proprietary database of 8,961 drug-metabolite pairs collected manually from bibliographic sources. Finally, post-marketing safety signals identified with statistical analyses of carefully curated data from FAERS reports offer key elements for the pharmacovigilance surveillance of drugs.

All data, both known and predicted, can be inspected using state-of-the-art analytics tools. The forthcoming release, version 4.0, will include a purposely designed MedChem Explorer module to facilitate SAR analyses and purchasing of compound analogues by medicinal chemists from the catalogues of selected chemical providers. The updated FAERS Explorer module provides access to 50 years of reports (from 1969 to 2019, 15.1M) and offers numerous enhancements including safety comorbidity analyses and stratified age versus weight analyses, in addition to the identification of emergent and consolidated signals.

Latest publications related to or using results obtained with CLARITY:

 

About Chemotargets

Founded on March 2006 as a spin-off company from Dr. Mestres’ Research Group on Systems Pharmacology under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets offers cutting-edge validated computational methodologies with top-market predictive performance. The company is currently recognized as a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient. 

 

For more information: e-mail clarity@chemotargets.com

 

Chemotargets will be present at the in-cosmetics Global event, 2nd-4th April 2019, Paris (France)

14 March 2019

Visit us at stand number P132

Chemotargets will be First time Exhibitor at the in-cosmetics Global event, which will take place on the 2nd-4th April 2019 in Paris (France). 

We will be present Chemotargets CLARITYⓇ v3.0, the integrative analytics platform for small molecule pharmaceuticals and cosmeceuticals, and the new Cosmetics Explore module.

For further information, to request a demo or schedule a meeting during the conference, please contact us at info@chemotargets.com.
 

Chemotargets SL will present CLARITY® v3.0 at SOT2019, 10-14th March 2019, Baltimore (US)

15 January 2019

Join us at booth number 4210 

Chemotargets will participate at the Society of Toxicology Annual meeting (SOT2019) in Baltimore, MD, March 10-14, 2019. We will be present Chemotargets CLARITY, the integrative analytics platform for small molecule pharmaceuticals and cosmeceuticals. The most advanced discovery informatics solution for predictive off-target pharmacology and safety of compounds and their metabolites, CLARITY is used by top pharma and regulatory bodies, including FDA CDER.

Join us at booth number 4210 (together with Bioinfogate) for a CLARITY demonstration. For further information or to schedule a meeting during the conference, please contact info@chemotargets.com.

 

Chemotargets SL launches the CLARITY® v3.0 release

06 November 2018

Updates on data and models, and a new analytics module to navigate FAERS data

 

This new version includes as improvements to previous release.

  • Updates of data and models processed:

DATA - An expertly curated training set of 2.6 million compounds derived from patents, journals and public databases to ensure comprehensive coverage of the chemical space.

MODELS - Pharmacology (3,601 targets) and Toxicology (7 Preclinical and 520 Clinical endpoints).

This module provides users with access to standardized contents of FAERS and analytics, including identification of emergent and consolidated signals, while being able to link them to drugs-targets-safety-metabolites-diseases.

  • An Indications tab in the Drug Explorer module.

  • Option to customized Pharmacology or Toxicology profiling, with a one-click custom panel creation by target family (e.g., kinases or nuclear receptors) or toxicology category (e.g., all endpoints related to CardioTox).

  • Higher GUI navigation speed and better global performance.

 

Request a demonstration at clarity@chemotargets.com 

New Research Collaboration Agreement (RCA) between the FDA-CDER (Center for Drug Evaluation and Research) and Chemotargets SL.

15 January 2018

The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health.

 

Barcelona / Washington D.C., USA: The Food and Drug Administration's Center for Drug Evaluation and Research (FDA/CDER) and Chemotargets will work together under a 5-year Research Collaboration Agreement (RCA).

The primary objective of the research agreement will be to assess the utility and performance of the Chemotargets CLARITY® intelligence & discovery platform to predict on-target and off-target activities using known pharmacology and safety data from experimental studies of small molecular entities.  Evaluating in silico models for broad pharmacological profiling is of interest to CDER to predict potential adverse events of drugs in development. Additionally, insight into a chemical’s molecular target profile can help predict abuse and addiction potential, which may reduce risks associated with exposure to these substances.

The collaboration will involve the use of the Chemotargets CLARITY® platform to evaluate hypotheses on the toxicological endpoints that are used by CDER to evaluate drug safety. The program identifies the probable molecular targets and mode of action of small molecules, and their predicted metabolites by simultaneously and rapidly screening in a single predictive model more than 2,000 mechanisms of action associated with therapeutic activity and safety liabilities, including hundreds of safety-related mechanisms annotated with preclinical toxicity and clinical adverse effects. In this respect, Chemotargets CLARITY® enables predictive compound safety based on careful treatment of FAERS data and the use of some mathematical descriptors to highlight drug safety signals from background noise. CDER will have access to a Chemotargets CLARITY® version based on an expertly-curated training set derived from internal curation efforts and selected patent data from the GOSTAR database produced by Excelra to ensure a comprehensive coverage of the chemical space. Chemical structure drawing capabilities are available and supported via the Chemaxon Marvin JS.

 

About FDA CDER

FDA/CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States.  As part of the FDA, CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs.  FDA/CDER's mission is to protect and promote public health by helping to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients.

 

About Chemotargets

Founded on March 2006 as a spin-off company from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets offers cutting-edge validated computational methodologies with top-market predictive performance. The innovation strategy is driven by access to state-of-the-art research performed at Dr. Mestres Lab @ IMIM, a leading academic center of excellence based in Barcelona.

Dr. Mestres is the author of more than 150 peer reviewed publications. Chemotargets is currently recognized as a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient.

The recent strategic investment in Chemotargets SL. by the Prous Institute for Biomedical Research will allow to accelerate product development and acquire new capabilities to support the company’s vision.

For more information: e-mail clarity@chemotargets.com

Chemotargets to Present at the Chem-Bio Informatics Society (CBI) Annual Meeting

Tokyo, Japan, October 24-27, 2017
02 October 2017

Chemotargets SL. has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting: “Drug Discovery and Development Pioneered by Data-Driven Research"” which takes place in Tokyo, Oct. 3-5, 2017.  

During the meeting, Dr. Jordi Mestres Ph.D.,  Chemotargets SL., Founder & President, will present two lectures:

“Chemotargets CLARITY: An Advanced Analytics Platform for Predictive Pharmacology and Safety”

The recent explosion of heterogenous data for millions of small molecules in a range of diverse areas of relevance to drug discovery offers a wealth of opportunities for using that data to build predictive models for pharmacology, safety and therapeutics but also poses challenges to develop advanced analytics tools that allow for visualizing its complexity in a highly compact and interpretable manner. Dr. Mestres will present the newly introduced platform Chemotargets CLARITY: an advanced analytics platform that allows for linking chemistry, pharmacology, and safety data.  During the seminar, several use cases will be presented, covering:

  • Extraction and visualization of pharmacology and safety data for small molecules available in public and patent databases
  • Prediction of the pharmacological profile of an early small molecule hit from HTS
  • Identification of potential safety liabilities due to the predicted off-target pharmacology
  • Prediction of metabolites and their pharmacological profiles as a source of safety liabilities
  • Exploiting the analytics tools provided to extract signals from all data generated

In his second presentation, “The Usefulness of In Silico Technologies to Minimize Off-Target Safety Pharmacology Events”, Dr Jordi Mestres will introduce specific examples in which comprehensive use of the in silico approach can support the design of an adequate off-target safety assessment strategy for novel investigational drugs.  Beyond the identification of simple structural alerts, access to pharmacological data for millions of small molecules, both from public and commercial sources, and post-marketing safety data for thousands of drugs, from the FDA Adverse Event Reporting System (FAERS), has allowed the development of a new generation of mechanism-based computational approaches to large-scale predictive drug safety. Applications to several use cases covering a variety of safety endpoints will be presented.

For further information or to schedule a meeting during the conference, please contact infochemo@chemotargets.com

About the Chem-Bio Informatics Society  

The Chem-BioInformatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society has interest in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.    

About Chemotargets

Founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performan- ce.

The innovation strategy is driven by new cutting edge methods generated at Dr. Mestres’ lab at IMIM, a leading academic center of excellence based in Barcelona. Dr. Mestres is the author of more than 150 peer-reviewed publica- tions.

Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.

Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency.

Prous Institute for Biomedical Research’s recent strategic investment in Chemotargets will allow product development to be accelerated and new capabilities to be acquired in order to support the company’s vision.

Prous Institute Signs Investment Agreement With Chemotargets

Investment to expand Chemotargets SL. portfolio of leading drug discovery solutions The transaction adds to a growing number of holdings of the Prous group in academic spin-off companies
06 June 2017

Barcelona, May 2017 – Prous Institute for Biomedical Research announced today that it has made a strategic investment in Chemotargets SL. Founded by Dr. Jordi Mestres as a spin-off of IMIM Hospital del Mar Medical Research Institute, Chemotargets is a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Financial terms of the transaction were not disclosed.

The investment will allow Chemotargets to expand its product development and accelerate its innovation plans in the drug discovery & development spaces. In addition, it will permit Chemotargets to grow its customer base and achieve a global presence in the pharmaceutical, healthcare and related industries.

As part of the agreement, Prous Institute will also leverage Chemotargets’ informatics solutions for its own drug discovery programs in the fields of cancer and neurodegeneration.

An immediate milestone of this agreement will be the introduction of a new big data analytics and visualization platform integrating chemistry, genomics, pharmacology, toxicology and therapeutics.

Big data is having an enormous impact in the finding of better and safer drugs. The use of advanced predictive analytics and visualization technologies enables the generation of new working hypotheses by seamlessly navigating within the enormous amount of data coming from modern biomedical research. Chemotargets’ platform optimizes research and development efforts by facilitating the existence of links between small molecules, their primary targets and secondary off-targets, the associated safety issues and the likely use in particular therapeutic areas.

Likewise, in the context of this transaction, the advanced computational approaches developed by Chemotargets will be evolved towards adapting the new platform to the new Precision Medicine paradigm.

“Chemotargets offers a state-of-the-art platform in its field and has a unique vision to develop it into a global solution for emerging applications in the life sciences, from initial drug discovery to clinical point of care” said Dr. Josep Prous, VP of Research & Development, Prous Institute. “We look forward to working closely with Dr Mestres’ team to maximize synergies and add value for customers.”

Dr. Jordi Mestres, Chemotargets' Founder & CEO commented: “We are very excited about this new partnership with Prous Institute which will allow us to accelerate our product development and innovation plans in the drug discovery space and continue to bring product upgrades and new enhancements to our growing number of end-users. Prous has over 50 years experience creating and managing biomedical knowledge and its reputation for the quality of its data and products is recognized worldwide. In this respect we highly value the agreement for what Prous will bring to Chemotargets beyond growth equity”.

Dr Joaquim Bellmunt, Director of IMIM, said: "Dr. Mestres is a Principal Investigator of IMIM and a pioneer in technology transfer within our Institution. We are delighted to see how our spin-off will be able to move to its next growth phase thanks to this strategic investment from Prous”.

 

About Prous Institute for Biomedical Research

Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Based on its longstanding expertise in the creation and management of biomedical knowledge, the company has drug discovery programs in the fields of cancer and neurodegeneration, which has led to various preclinical candidates. Additionally, Prous Institute has invested in numerous companies in the field of life sciences including drug discovery, medical diagnostics, medical imaging or enabling technologies organizations.

About Chemotargets

Chemotargets S.L. is a computationally-oriented biotech company focused on the drug discovery and development areas. Located in Barcelona, it was founded in March 2006 as a spin-off initiative from the Chemogenomics Laboratory under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient. To this end, Chemotargets has designed, and continues to develop, an integrated technology platform involving a broad spectrum of cutting-edge computational methodologies.

About IMIM

The IMIM Hospital del Mar Medical Research Institute is a public body dedicated to scientific research in the field of Biomedicine and Health Sciences. Located at the Barcelona Biomedical Research Park (PRBB), IMIM is up to 82%, made up of research groups lead by professionals from the MAR Health Park, most of whom are associates of the Autonomous University of Barcelona (UAB) and the Pompeu Fabra University (UPF), as well as other seconded staff members from the Barcelona Institute for Global Health (ISGlobal), the Centre for Genomic Regulation (CRG), the Department of Experimental and Health Sciences of the Pompeu Fabra University (DCEXS-UPF), the Centre of Regenerative Medicine in Barcelona (CMRB) and the Barcelona Biomedical Research Park (PRBB).


For further information, please contact:

Atrevia
Mercè Mascarell
Tel. +34 93 419 06 30
MMASCARELL@ATREVIA.COM

Communication Department IMIM
Rosa Manaut
Tel. +34 618 509 885
RMANAUT@IMIM.ES